Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
Status:
Completed
Trial end date:
2022-02-26
Target enrollment:
Participant gender:
Summary
Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a
decrease in bone mineral density that causes bone fragility and increases the risk of
fractures during menopause. Recently, a high prevalence of hypovitaminosis D has been found
worldwide, which could trigger a state of secondary hyperparathyroidism that can worsen the
state of postmenopausal patients with osteoporosis. An open-label, clinical trial was
conducted in Mexican women with postmenopausal osteopenia-osteoporosis to determine the
efficacy of the combined treatment with risedronate and high-dose vitamin D in improving bone
mineral density, hyperparathyroidism, and hypovitaminosis D.
Phase:
N/A
Details
Lead Sponsor:
Hospital Regional 1o de Octubre
Collaborators:
National Polytechnic Institute, Mexico Universidad Nacional Autonoma de Mexico